QGEN FINANCIAL STATEMENTS

Qiagen NV — balance sheet, income statement and cash flow trends

QGENQiagen NV

🇺🇸 USA · NYSE · Healthcare · Diagnostics & Research

Value it Duel

Income Statement

Quarterly progression — trailing-twelve-month values

RevenueNet Income

Profit Funnel

Q1 2026 · TTM

Percentages are relative to revenue.

Key Figures

YoY change

Revenue2.1 B $+4.8%

Gross Profit1.3 B $+31.2%

Operating Income521.6 M $+341.6%

EBITDA777.9 M $+109.1%

Net Income402.2 M $+329.3%

Peer Comparison· Diagnostics & Research

Company	Rev. Growth	Gross Margin	EBITDA Margin	Net Margin
QGEN	4.8%	61.6%	37.1%	19.2%
SHL	11.4%	29.6%	17.3%	5.2%
ERF	5.0%	12.3%	19.9%	6.5%
Industry median	9.1%	53.0%	18.8%	6.7%

Company	Rev. Growth	Gross Margin	EBITDA Margin	Net Margin
QGEN	4.8%	61.6%	37.1%	19.2%
CRL	0.1%	31.9%	7.2%	-4.6%
TWST	17.8%	52.1%	-13.8%	-19.8%
RVTY	4.8%	51.4%	26.6%	8.3%
RDNT	14.7%	9.4%	15.1%	-0.7%
SHC	7.4%	55.0%	41.1%	9.9%
Industry median	9.1%	53.0%	18.8%	6.7%

Balance Sheet

Quarterly period-end values

Total AssetsTotal LiabilitiesEquity

Capital Structure

Q1 2026

Equity3.3 B $58%
Current Liabilities479.1 M $8%
Long-term Liabilities2 B $34%

Key Figures

YoY change

Total Assets5.8 B $+4.3%

Total Liabilities2.5 B $+14.6%

Total Equity3.3 B $-2.2%

Cash & ST Investments646.3 M $-32.9%

Total Debt1.6 B $+16.9%

Net Debt1 B $+30.0%

Peer Comparison· Diagnostics & Research

Company	Current Ratio	Debt/Equity	NetDebt/EBITDA	Equity/Assets
QGEN	3.21	49.4%	1.29	57.6%
SHL	1.01	85.8%	3.78	50.3%
ERF	1.09	153.3%	3.20	32.3%
Industry median	1.87	49.3%	1.92	50.1%

Company	Current Ratio	Debt/Equity	NetDebt/EBITDA	Equity/Assets
QGEN	3.21	49.4%	1.29	57.6%
CRL	1.36	103.9%	9.86	38.0%
TWST	2.70	21.1%	1.35	67.3%
RVTY	1.72	46.6%	3.22	59.9%
RDNT	1.17	179.0%	4.56	27.8%
SHC	2.82	364.7%	4.00	19.2%
Industry median	1.87	49.3%	1.92	50.1%

Cash Flow Statement

Quarterly progression — trailing-twelve-month values

Operating Cash FlowCapital ExpendituresFree Cash Flow

Cash Flow Bridge

Q1 2026 · TTM

Key Figures

YoY change

Operating Cash Flow615.2 M $-9.6%

Capital Expenditures204.7 M $+15.8%

Free Cash Flow410.5 M $-18.5%

Dividends Paid-54.2 M $—

Peer Comparison· Diagnostics & Research

Company	CF Margin	FCF Margin	CapEx Ratio	CF/Net Income
QGEN	29.3%	19.6%	9.8%	153.0%
SHL	13.1%	8.3%	4.7%	251.9%
ERF	17.7%	7.3%	10.4%	272.6%
Industry median	16.3%	9.7%	4.5%	110.1%

Company	CF Margin	FCF Margin	CapEx Ratio	CF/Net Income
QGEN	29.3%	19.6%	9.8%	153.0%
CRL	15.1%	9.7%	5.4%	-328.7%
TWST	-13.6%	-23.2%	9.7%	68.4%
RVTY	19.7%	17.0%	2.7%	237.1%
RDNT	16.3%	-6.9%	23.2%	-2,463.4%
SHC	22.0%	8.1%	13.8%	221.7%
Industry median	16.3%	9.7%	4.5%	110.1%

Amounts are in the company’s reporting currency. Peer comparison tables use ratio-based metrics so currency differences do not distort the picture.

Go deeper on QGEN

Run a DCF valuation

Full DCF model with editable assumptions

Start a head-to-head duel

Compare two stocks metric by metric

Filter in the stock screener

Build your own universe with 400+ metrics

Data on this page refreshes once per day. Price data as of Jul 7, 26. This content is for informational purposes only and is not investment advice.